These funds will allow moving into clinical trials Minoryx’s candidate for X-linked Adrenoleukodystrophy, and further develop its platform for identifying non-competitive pharmacological chaperones. ”la Caixa” is leading this operation through the Caixa Innvierte BioMed II fund, joined by the Sanfilippo Foundation Switzerland .Minoryx has raised 1.6 million Euro in a round led by ”la Caixa”. The investment has been made through the Caixa Innvierte BioMed II fund, an investment vehicle managed by Caixa Capital Risc, the venture capital arm of ”la Caixa”, which has participation from the Centre for Industrial Technology Development (Centro para el Desarrollo Tecnológico Industrial, CDTI), under the Programa Innvierte framework, and with a minority participation by the Catalan Institute of Finance (Institut Català de Finances, ICF). The operation is joined by the Sanfilippo Foundation Switzerland view pdf